Quick Answer
Esperion Therapeutics, Inc. reported Stockholders Equity of -$301.96 million for fiscal year 2025.
Esperion Therapeutics, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | -$301.96M | +22.3% |
| 2024 | -$388.72M | +14.6% |
| 2023 | -$454.99M | -40.5% |
| 2022 | -$323.78M | -64.4% |
| 2021 | -$196.94M | -104.9% |
| 2020 | -$96.13M | -581.9% |
| 2019 | $19.95M | -74.8% |
| 2018 | $79.12M | -67.7% |
| 2017 | $244.69M | +7.0% |
| 2016 | $228.60M | -20.4% |
| 2015 | $287.26M | +115.1% |
| 2014 | $133.55M | +80.3% |
| 2013 | $74.09M | +279.1% |
| 2012 | -$41.37M | -37.7% |
| 2011 | -$30.03M | -55.5% |
| 2010 | -$19.31M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$451.36M | -21.9% | -4.1% |
| June 30, 2025 | -$433.51M | -25.9% | -1.7% |
| March 31, 2025 | -$426.21M | -44.8% | -9.6% |
| December 31, 2024 | -$388.72M | +14.6% | -5.0% |
| September 30, 2024 | -$370.21M | +9.7% | -7.6% |
| June 30, 2024 | -$344.22M | +7.5% | -17.0% |
| March 31, 2024 | -$294.30M | +10.7% | +35.3% |
| December 31, 2023 | -$454.99M | -40.5% | -11.0% |
- Esperion Therapeutics, Inc. showed an increase of +22.3% in Stockholders Equity compared to the prior fiscal year.
- Over the 2010–2025 period, Esperion Therapeutics, Inc.’s stockholders equity has declined by 1463.5% (from -$19.31 million to -$301.96 million).
- The most recent figure is from Esperion Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 10, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: